1. Pink Sheet
  2. >>Geography
  3. >>Europe

Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey

 
• By Neena Brizmohun

Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.

Share close up view of human eye with data illustration, robotic concept
Vabysmo is approved for treating the eye diseases wet AMD and DME • Source: Alamy

Health technology assessment institute NICE has recommended that Roche’s Vabysmo (faricimab) be funded via the National Health Service in England, where thousands of people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME) could be eligible to receive the VEGF therapy.

By contrast, it advised that Alnylam Pharmaceuticals’ Oxlumo (lumasiran), for primary hyperoxaluria type 1 (PH1), and Vifor Pharma’s Tavneos (avacopan), for treating inflammatory conditions of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe